FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/21/2026
Back to search
Official data from USPTO
AXCYNSIS AXCYNSIS THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
05/22/2026
Trademark type
Combined
Nice classes
5, 42, 44
Filing date
07/23/2024
Registration date
10/21/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/21/2025
Last transaction
05/22/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
24
Owner location
SG
Examiner
DIEFENBACH, LINDSEY OLSON
Law office
O90
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the stylized wording "AXCYNSIS" in which the lettering "AXC" is formed by a blue geometric figure with connecting diagonal and horizontal lines resembling a molecular model, the letter "Y" appears in teal and is angled to one side and surrounded by two teal diagonal lines also resembling an Antibody, and the lettering "NSIS" appears in teal stylized font. All of the foregoing appears above the stylized black wording "AXCYNSIS THERAPEUTICS". The color white represents background and is not claimed as a feature of the mark.
Holders and representatives
Holders
AXCYNSIS THERAPEUTICS PTE. LTD.
Representatives
Joseph G. Chu JCIP
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for use in oncology; pharmaceutical drugs being pharmaceutical preparations for use in the treatment of cancer; pharmaceutical productspharmaceutical preparations for suppressing tumors; biopharmaceutical preparations for the treatment of cancer; chemical preparations for pharmaceutical purposesfor oncology.
Class 42
Development of pharmaceuticals; pharmaceutical research and development; research and development for the pharmaceutical industry; biochemical research; biochemical research and analysis; biochemical research and development; biochemistry research services; bioinorganic chemistry research; biological research; biological research and analysis; biological research laboratory services; biological research services; biomedical research services; bioorganic chemistry research; biotechnological research; biotechnology research; chemical research; chemical research and analysis; chemical research and analysis services; chemical research laboratory services; chemical research services; technological research in the field of chemistry; chemistry research; clinical research in the field of antibody drug conjugates in oncology; consultancy in the field of pharmaceutical research; consultancy in the field of scientific research; consultancy in the field of technological research relating to pharmaceutical studies; consultancy relating to pharmaceutical research and development; consultancy relating to pharmaceutical research and development in the field of therapeutics; DNA analysis services for scientific research purposes; DNA screening for scientific research purposes; DNA sequencing being DNA analysis for medical research purposes; DNA sequencing technology research; gene therapy research; scientific research in the field of genetics and antibody drug conjugates; genetic testing for scientific research purposes; laboratory research in the fields of antibody drug conjugates in oncology and antibody drug conjugate development; laboratory research in the field of chemistry; laboratory research in the field of gene expression; laboratory research in the field of pharmaceuticals; laboratory research services relating to pharmaceuticals; medical research; medical research in the field of oncology; medical research laboratory services; medical research services; pharmaceutical research and development services; pharmaceutical research consultancy; pharmaceutical research services; chemical research services in the nature of preparation of scientific reports relating to chemical research; scientific research services in the nature of preparation of scientific reports relating to scientific research; product research; product research and development; providing information about medical and scientific research in the field of pharmaceuticals; providing information relating to scientific research in the fields of biochemistry and biotechnology; providing information and online information about scientific and technological services in the field of antibody drug conjugates in oncology and research and design relating thereto; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; provision of information relating to scientific research; provision of information relating to technological research in the field of antibody drug conjugates in oncology; research servicesscientific research; research and development in the field of biotechnology; research and development of new products; research and development of new products for others; research and development services for the pharmaceutical industry; research and development services in the field of antibodies; research and development services in the field of antibody technology; research and development services in the field of biochemistry; research and development services in the field of biotechnology; research and development services in the field of chemistry; research and development services in the field of pharmaceutical preparations; research in the field of biology; research in the field of biomedicine; research in the field of biotechnology; research in the field of chemistry; research on the subject of pharmaceuticals; research relating to biotechnology; research relating to chemistry; research relating to chemicals; research relating to medicine in the nature of medical research; research relating to molecular sciences; research relating to pharmaceuticals; research relating to science; research laboratory analysis services in the field of chemistry and bioconjugation; research to develop new products; scientific and industrial research in the field of antibody drug conjugates in oncology; scientific and technological servicesresearch and design in the field of antibody drug conjugates in oncology; scientific and technological servicesresearch and development in the field of antibody drug conjugates in oncology; scientific research; scientific research and analysis for scientific research purposes; scientific research and development; scientific research for medical purposes; scientific research for medical purposes in the area of cancerous diseases; scientific research in the field of biotechnology; scientific research into the development of new products; scientific research relating to biology; scientific research relating to chemistry; scientific research relating to chemical products; scientific research relating to genetics; scientific research services; technical research in the field of pharmaceutical studies; technical research projects and studies in the field of antibody drug conjugates in oncology.
Class 44
Medical testing services in the nature of in vitro testing for medical diagnostic and treatment purposes and in vitro testing of pharmaceuticals; medical analysis services in the nature of in vitro analysis for medical diagnostic and treatment purposes and in vitro analysis in the nature of testinginspectionresearch of pharmaceuticals.
Publications
History of USPTO decisions and trademark events.
29 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
04/30/2026
FIMP
FINAL DISPOSITION PROCESSED
04/30/2026
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
04/09/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/23/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
03/23/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/21/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/21/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
10/21/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/02/2025
PUBO
PUBLISHED FOR OPPOSITION
09/02/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/27/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/29/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
07/28/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
07/28/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
07/28/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
07/28/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/25/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/24/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/24/2025
RFNT
REFUSAL PROCESSED BY IB
03/22/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/04/2025
RFRR
REFUSAL PROCESSED BY MPU
03/04/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/16/2025
CNRT
NON-FINAL ACTION WRITTEN
01/15/2025
DOCK
ASSIGNED TO EXAMINER
01/10/2025
MAFR
APPLICATION FILING RECEIPT MAILED
11/08/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/08/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/24/2024
Continuous trademark protection
Get notified about every new filing that threatens AXCYNSIS AXCYNSIS THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.